
This could prove a make-or-break year for Valeant.The specialist drug company begins 2016 with a reputation damaged by allegations of …

Troubled Valeant Pharmaceuticals last week announced strong third quarter revenues, reporting a 36% increase in revenues to $172 million, but …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

